NGVT / Ingevity Corporation - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 3, 2025 Date of Report (date of earliest event reported) INGEVITY CORPORA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 3, 2025 Date of Report (date of earliest event reported) INGEVITY CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37586 47-4027764 (State or other jurisdiction of incorporation or organizatio

Ingevity Corporation

Exhibit 99.1 Ingevity Corporation 4920 O’Hear Avenue Suite 400 North Charleston, S.C. 29405 USA www.ingevity.com News Contact: Caroline Monahan 843-740-2068 [email protected] Investors: John E. Nypaver, Jr. 843-740-2002 [email protected] Ingevity announces agreement to sell North Charleston crude tall oil refinery and majority of Industrial Specialties product line to Mainstream P

ASSET PURCHASE AGREEMENT BY AND BETWEEN INGEVITY CORPORATION, MAINSTREAM PINE PRODUCTS, LLC September 3, 2025 TABLE OF CONTENTS

Exhibit 2.1 Execution Version ASSET PURCHASE AGREEMENT BY AND BETWEEN INGEVITY CORPORATION, AND MAINSTREAM PINE PRODUCTS, LLC September 3, 2025 TABLE OF CONTENTS Article I DEFINITIONS AND CONSTRUCTION 6 Section 1.01 Definitions 6 Article II PURCHASE AND SALE 23 Section 2.01 Purchase and Sale of Assets 23 Section 2.02 Excluded Assets 25 Section 2.03 Assumed Liabilities 26 Section 2.04 Excluded Liab

TERMS AND CONDITIONS

Exhibit 10.4 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. SUCH EXCLUDED INFORMATION IS DENOTED BY ASTERISKS IN BRACKETS [*****]. Ingevity Corporation Restricted Stock Unit Awards (Performance-Based—2025) TERMS AND CONDITIONS 1.Terms and Conditions: This grant of performan

Terms and Conditions

Exhibit 10.8 Ingevity Corporation Incentive Compensation Awards (for 2025) International Participants (Service-Based Cash) Terms and Conditions 1.Terms and Conditions: This service-based cash award is made under the Ingevity Corporation 2025 Omnibus Incentive Plan (the “Plan”), and is subject in all respects to the terms of the Plan. All terms of the Plan are hereby incorporated into these terms a

Terms and Conditions

Exhibit 10.5 Ingevity Corporation Restricted Stock Unit Awards (for 2025) (Service-Based) Terms and Conditions 1.Terms and Conditions: This grant of service-based restricted stock units is made under the Ingevity Corporation 2025 Omnibus Incentive Plan (the “Plan”), and is subject in all respects to the terms of the Plan. All terms of the Plan are hereby incorporated into these terms and condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37586 INGEVITY CORPORATION (Exact name of registrant as speci

Terms and Conditions

Exhibit 10.7 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. SUCH EXCLUDED INFORMATION IS DENOTED BY ASTERISKS IN BRACKETS [*****]. Ingevity Corporation Incentive Compensation Awards (for 2025) International Participant (Performance-Based) Terms and Conditions 1.Terms and Co

INGEVITY CORPORATION First Amendment to the Amended and Restated 2017 Ingevity Corporation Employee Stock Purchase Plan

Exhibit 10.9 INGEVITY CORPORATION First Amendment to the Amended and Restated 2017 Ingevity Corporation Employee Stock Purchase Plan By action of the Board of Directors of Ingevity Corporation (the “Company”), the Amended and Restated 2017 Ingevity Corporation Employee Stock Purchase Plan (the “Plan”) is amended as set forth herein, effective as of June 1, 2025: 1.Section 9(a) of the Plan is amend

TERMS AND CONDITIONS

Exhibit 10.3 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. SUCH EXCLUDED INFORMATION IS DENOTED BY ASTERISKS IN BRACKETS [*****]. Ingevity Corporation Restricted Stock Unit Awards (Performance-Based—2025) TERMS AND CONDITIONS 1.Terms and Conditions: This grant of performan

Terms and Conditions

Exhibit 10.6 Ingevity Corporation Restricted Stock Unit Awards (for 2025) (Service-Based) Terms and Conditions 1.Terms and Conditions: This grant of service-based restricted stock units is made under the Ingevity Corporation 2025 Omnibus Incentive Plan (the “Plan”), and is subject in all respects to the terms of the Plan. All terms of the Plan are hereby incorporated into these terms and condition

[Signature page follows]

Exhibit 10.10 July 1, 2025 S. Edward Woodcock [address] Dear Ed: This letter agreement (the “Letter Agreement”) is written to set forth the mutually-agreed-upon terms and conditions for the termination of your employment with Ingevity Corporation (“Ingevity” or the “Company”). *** YOU AND INGEVITY AGREE: THIS LETTER AGREEMENT IS SUBJECT TO BINDING ARBITRATION UNDER THE FEDERAL ARBITRATION ACT ("FA

TABLE OF CONTENTS FINANCIAL SCHEDULES Page Condensed Consolidated Statements of Operations 1 Segment Operating Results 2 Condensed Consolidated Balance Sheets 4 Condensed Consolidated Statements of Cash Flows 5 Non-GAAP Financial Measures 6 Reconcili

Exhibit 99.1 Ingevity Corporation 4920 O'Hear Avenue Suite 400 North Charleston, SC 29405 USA www.ingevity.com News Contact: Caroline Monahan 843-740-2068 [email protected] Investors: John E. Nypaver, Jr. 843-740-2002 [email protected] Ingevity reports second quarter 2025 financial results HIGHLIGHTS: •Net sales of $365.1 million, down 7% compared to prior year, primarily due to lower sales

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 August 4, 2025 Date of Report (date of earliest event reported) INGEVITY CORPORATI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 August 4, 2025 Date of Report (date of earliest event reported) INGEVITY CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37586 47-4027764 (State or other jurisdiction of incorporation or organization)

Ingevity Corporation

Exhibit 99.1 Ingevity Corporation 4920 O’Hear Avenue Suite 400 North Charleston, S.C. 29405 USA www.ingevity.com Contact: News Caroline Monahan 843-740-2068 [email protected] Investors: John E. Nypaver, Jr. 843-740-2002 [email protected] Ingevity announces departure of Performance Materials segment president, Ed Woodcock NORTH CHARLESTON, S.C., July 1, 2025 – Ingevity Corporation

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 July 1, 2025 Date of Report (date of earliest event reported) INGEVITY CORPORATION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 July 1, 2025 Date of Report (date of earliest event reported) INGEVITY CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37586 47-4027764 (State or other jurisdiction of incorporation or organization) (

Calculation of Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Tables S-8 (Form Type) Ingevity Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1)(2) Proposed Maximum Offering Price Per Unit(3) Maximum Aggregate Offering Price(3) Fee Rate Amount of Registration Fee Equity Common Stock, $0.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933 INGEVITY CORPORATION (Exact name of registrant as specified in its charter)

As filed with the Securities and Exchange Commission on May 7, 2025 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 FORM S-8 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933 INGEVITY CORPORATION (Exact name of registrant as specified in its charter)

As filed with the Securities and Exchange Commission on May 7, 2025 Registration No.

March 7, 2025

Exhibit 10.1 March 7, 2025 David H. Li [address] Dear Dave, We are pleased to provide written confirmation of our offer of employment with Ingevity Corporation (“Ingevity”) as President and Chief Executive Officer reporting to Ingevity’s Board of Directors (“Board”) based at our global headquarters in North Charleston, South Carolina, effective on April 7, 2025 (the “Start Date”). It is expected t

THE SCHEDULE Individual Terms

Exhibit 10.3 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. SUCH EXCLUDED INFORMATION IS DENOTED BY ASTERISKS IN BRACKETS [*****]. DWF Final TXS 7 March 2025 (1) INGEVITY UK LIMITED and (2) MICHAEL SHUKOV SERVICE AGREEMENT DWF Law LLP 5 St Paul's Square Old Hall Street Live

SEVERANCE AND CHANGE OF CONTROL AGREEMENT

Exhibit 10.2 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. SUCH EXCLUDED INFORMATION IS DENOTED BY ASTERISKS IN BRACKETS [*****]. SEVERANCE AND CHANGE OF CONTROL AGREEMENT THIS SEVERANCE AND CHANGE OF CONTROL AGREEMENT (the “Agreement”) by and between Ingevity Corporation,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37586 INGEVITY CORPORATION (Exact name of registrant as spec

TABLE OF CONTENTS FINANCIAL SCHEDULES Page Condensed Consolidated Statements of Operations 1 Segment Operating Results 2 Condensed Consolidated Balance Sheets 4 Condensed Consolidated Statements of Cash Flows 5 Non-GAAP Financial Measures 6 Reconcili

Exhibit 99.1 Ingevity Corporation 4920 O'Hear Avenue Suite 400 North Charleston, SC 29405 USA www.ingevity.com News Contact: Caroline Monahan 843-740-2068 [email protected] Investors: John E. Nypaver, Jr. 843-740-2002 [email protected] Ingevity reports first quarter 2025 financial results HIGHLIGHTS: •Net sales of $284.0 million, down 17% compared to prior year, primarily due to repositionin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 May 5, 2025 Date of Report (date of earliest event reported) INGEVITY CORPORATION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 May 5, 2025 Date of Report (date of earliest event reported) INGEVITY CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37586 47-4027764 (State or other jurisdiction of incorporation or organization) (C

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 April 30, 2025 Date of Report (date of earliest event reported) INGEVITY CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37586 47-4027764 (State or other jurisdiction of incorporation or organization)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. __)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [ ] Filed by a Party other than the Registrant [X] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

COOPERATION AGREEMENT

Exhibit 10.1 EXECUTION COOPERATION AGREEMENT This Cooperation Agreement (this “Agreement”), dated as of March 30, 2025 (the “Effective Date”), is made by and among Ingevity Corporation, a Delaware corporation (the “Company”), and the persons set forth under the “Vision One Parties” caption in the signature pages hereto and their Affiliates or Associates (collectively, the “Vision One Parties”) (th

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 30, 2025 Date of Report (date of earliest event reported) INGEVITY CORPORATIO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 30, 2025 Date of Report (date of earliest event reported) INGEVITY CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37586 47-4027764 (State or other jurisdiction of incorporation or organization)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.      )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.      ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14-a6(e)(2)) ☒ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14-a6(e)(2)) ☐ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.      )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.      ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☑ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) ☑ Filed by the Registrant ☐ Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ☑ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14-a6(e)(2)) ☐ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.      )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.      ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 March 10, 2025 Date of Report (date of earliest event reported) INGEVITY CORPORATI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 March 10, 2025 Date of Report (date of earliest event reported) INGEVITY CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37586 47-4027764 (State or other jurisdiction of incorporation or organization)

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 March 10, 2025 Date of Report (date of earliest event reported) INGEVITY CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37586 47-4027764 (State or other jurisdiction of incorporation or organization)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ☑ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.      )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.      ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐

Ingevity Corporation

Exhibit 99.1 Ingevity Corporation 4920 O’Hear Avenue Suite 400 North Charleston, S.C. 29405 USA www.ingevity.com News Contact: Caroline Monahan 843-740-2068 [email protected] Investors: John E. Nypaver, Jr. 843-740-2002 [email protected] Ingevity announces appointment of David H. Li as president and CEO Li brings 25-year+ record of driving successful corporate transformation, long

1 Unveil the Industrial Powerhouse March 6, 2025

Exhibit 1 1 Unveil the Industrial Powerhouse March 6, 2025 ABOUT VISION ONE Vision One Fund, LP (together with its affiliates, “Vision One”) is a value - focused, governance - oriented investment firm based in Miami, Florida .

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. __)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [ ] Filed by a Party other than the Registrant [X] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.      )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.      ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐

1 Unveil the Industrial Powerhouse February 25, 2025

Exhibit 1 1 Unveil the Industrial Powerhouse February 25, 2025 ABOUT VISION ONE Vision One Fund, LP (together with its affiliates, “Vision One”) is a value - focused, governance - oriented investment firm based in Miami, Florida .

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. __)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [ ] Filed by a Party other than the Registrant [X] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

October 2, 2024

Exhibit 10.80 October 2, 2024 Dear Luis, Ingevity remains committed to fostering excellence and ensuring our collective success. As we proceed with the CEO transition, your leadership is crucial to enabling us to maintain our upward trajectory. With this in mind, it is my pleasure to share the details of your Ingevity Long-Term Incentive Plan award for 2024 relating to your service as interim Pres

{See next page for Acknowledgement and Certification Form}

Exhibit 19.1 POLICY NAME: SECURITIES AND INSIDER TRADING POLICY DEPT/GROUP: LAW AND COMPLIANCE POLICY SCOPE: DIRECTORS, DESIGNATED OFFICERS, EMPLOYEES POLICY REGION: GLOBAL EFFECTIVE DATE: February 16, 2023 PAGES 10 This Securities and Insider Trading Policy (this “Policy”) concerns the handling of material, non-public information relating to Ingevity Corporation, its wholly-owned direct and indir

Terms and Conditions

Exhibit 10.81 Ingevity Corporation Restricted Stock Unit Awards (for 2024) (Service-Based Interim CEO) Terms and Conditions 1.Terms and Conditions: This grant of service-based restricted stock units is made under the Ingevity Corporation 2016 Omnibus Incentive Plan (the “Plan”), and is subject in all respects to the terms of the Plan. All terms of the Plan are hereby incorporated into these terms

October 1, 2024

Exhibit 10.74 October 1, 2024 Ed Woodcock [Address] Dear Ed, Ingevity remains committed to fostering excellence and ensuring our collective success. As we proceed with the CEO transition, your leadership is crucial to enabling us to maintain our upward trajectory. With this in mind, it is my pleasure to share the details of your Incentive Compensation Award granted under Ingevity’s 2016 Omnibus In

October 2, 2024

Exhibit 10.79 October 2, 2024 Luis Fernandez-Moreno [Address] Dear Luis, We are pleased to provide written confirmation of our offer of employment with Ingevity Corporation ("lngevity") as Interim President and Chief Executive Officer ("Interim CEO"), reporting to lngevity's Board of Directors (the "Board"), based at our global headquarters in North Charleston, South Carolina, effective on October

October 1, 2024

Exhibit 10.76 October 1, 2024 Terry Dyer [Address] Dear Terry, Ingevity remains committed to fostering excellence and ensuring our collective success. As we proceed with the CEO transition, your leadership is crucial to enabling us to maintain our upward trajectory. With this in mind, it is my pleasure to share the details of your Incentive Compensation Award granted under Ingevity’s 2016 Omnibus

October 1, 2024

Exhibit 10.73 October 1, 2024 Mary Dean Hall [Address] Dear Mary, Ingevity remains committed to fostering excellence and ensuring our collective success. As we proceed with the CEO transition, your leadership is crucial to enabling us to maintain our upward trajectory. With this in mind, it is my pleasure to share the details of your Incentive Compensation Award granted under Ingevity’s 2016 Omnib

INGEVITY CORPORATION SUBSIDIARIES OF THE REGISTRANT Name of Subsidiary Jurisdiction of Organization Ingevity Corporation Delaware, United States of America Ingevity South Carolina, LLC Delaware, United States of America Ingevity Virginia Corporation

Exhibit 21.1 INGEVITY CORPORATION SUBSIDIARIES OF THE REGISTRANT Name of Subsidiary Jurisdiction of Organization Ingevity Corporation Delaware, United States of America Ingevity South Carolina, LLC Delaware, United States of America Ingevity Virginia Corporation Virginia, United States of America Ingevity Arkansas, LLC Delaware, United States of America Ingevity Services, Inc. Delaware, United Sta

Terms and Conditions

Exhibit 10.72 Ingevity Corporation Incentive Compensation Awards (for 2024) Executive Team (Service-Based Cash) Terms and Conditions 1.Terms and Conditions: This service-based cash award is made under the Ingevity Corporation 2016 Omnibus Incentive Plan (the “Plan”) and is subject in all respects to the terms of the Plan. All terms of the Plan are hereby incorporated into these terms and condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37586 INGEVITY CORPORATION (Exact name of registrant as specified

October 1, 2024

Exhibit 10.75 October 1, 2024 Ryan Fisher [Address] Dear Ryan, Ingevity remains committed to fostering excellence and ensuring our collective success. As we proceed with the CEO transition, your leadership is crucial to enabling us to maintain our upward trajectory. With this in mind, it is my pleasure to share the details of your Incentive Compensation Award granted under Ingevity’s 2016 Omnibus

Restrictive Covenants

Exhibit 10.78 Ingevity Corporation Incentive Compensation Awards (for 2025) Executive Team (Service-Based Cash) TERMS AND CONDITIONS 1.Terms and Conditions: This service-based cash award is made under the Ingevity Corporation 2016 Omnibus Incentive Plan (the “Plan”) and is subject in all respects to the terms of the Plan. All terms of the Plan are hereby incorporated into these terms and condition

January 1, 2025

Exhibit 10.77 January 1, 2025 Rich White [Address] Dear Rich, Ingevity remains committed to fostering excellence and ensuring our collective success. As we proceed with the CEO transition, your leadership is crucial to enabling us to maintain our upward trajectory. With this in mind, it is my pleasure to share the details of your Incentive Compensation Award granted under Ingevity’s 2016 Omnibus I

TABLE OF CONTENTS FINANCIAL SCHEDULES Page Condensed Consolidated Statements of Operations 1 Segment Operating Results 2 Condensed Consolidated Balance Sheets 4 Condensed Consolidated Statements of Cash Flows 5 Non-GAAP Financial Measures 6 Reconcili

Exhibit 99.1 Ingevity Corporation 4920 O'Hear Avenue Suite 400 North Charleston, SC 29405 USA www.ingevity.com News Contact: Caroline Monahan 843-740-2068 [email protected] Investors: John E. Nypaver, Jr. 843-740-2002 [email protected] Ingevity reports fourth quarter and full year 2024 financial results Fourth Quarter: •Net sales of $298.8 million decreased 20% compared to prior year primari

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 February 18, 2025 Date of Report (date of earliest event reported) INGEVITY CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37586 47-4027764 (State or other jurisdiction of incorporation or organizati

Regulation FD Disclosure, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 January 16, 2025 Date of Report (date of earliest event reported) INGEVITY CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37586 47-4027764 (State or other jurisdiction of incorporation or organizatio

Ingevity Corporation 4920 O'Hear Avenue Suite 400 North Charleston, SC 29405 USA www.ingevity.com News Contact: Caroline Monahan 843-740-2068 [email protected] Investors: John E. Nypaver, Jr. 843-740-2002 [email protected]

Exhibit 99.1 Ingevity Corporation 4920 O'Hear Avenue Suite 400 North Charleston, SC 29405 USA www.ingevity.com News Contact: Caroline Monahan 843-740-2068 [email protected] Investors: John E. Nypaver, Jr. 843-740-2002 [email protected] Ingevity announces plans to explore strategic alternatives for Performance Chemicals Industrial Specialties product line and North Charleston CTO refinery; re

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 December 16, 2024 Date of Report (date of earliest event reported) INGEVITY CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37586 47-4027764 (State or other jurisdiction of incorporation or organizati

Ingevity Corporation 4920 O'Hear Avenue Suite 400 North Charleston, SC 29405 USA www.ingevity.com News Contact: Caroline Monahan 843-740-2068 [email protected] Investors: John E. Nypaver, Jr. 843-740-2002 [email protected]

Exhibit 99.1 Ingevity Corporation 4920 O'Hear Avenue Suite 400 North Charleston, SC 29405 USA www.ingevity.com News Contact: Caroline Monahan 843-740-2068 [email protected] Investors: John E. Nypaver, Jr. 843-740-2002 [email protected] Ingevity elects Kevin Willis to its board of directors Accomplished chemical industry CFO brings substantial finance and capital management expertise and expe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37586 INGEVITY CORPORATION (Exact name of registrant as

Terms and Conditions

Exhibit 10.2 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. SUCH EXCLUDED INFORMATION IS DENOTED BY ASTERISKS IN BRACKETS [*****]. Ingevity Corporation Form of Restricted Stock Unit Award for U.K. Employees (first used in 2024) Restricted Stock Unit Awards (Performance-Base

Terms and Conditions

Exhibit 10.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. SUCH EXCLUDED INFORMATION IS DENOTED BY ASTERISKS IN BRACKETS [*****]. Ingevity Corporation Form of Restricted Stock Unit Award for U.S. Employees (first used in 2024) Restricted Stock Unit Awards (Performance-Base

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 October 29, 2024 Date of Report (date of earliest event reported) INGEVITY CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37586 47-4027764 (State or other jurisdiction of incorporation or organizatio

TABLE OF CONTENTS FINANCIAL SCHEDULES Page Condensed Consolidated Statements of Operations 1 Segment Operating Results 2 Condensed Consolidated Balance Sheets 4 Condensed Consolidated Statements of Cash Flows 5 Non-GAAP Financial Measures 6 Reconcili

Exhibit 99.1 Ingevity Corporation 4920 O'Hear Avenue Suite 400 North Charleston, SC 29405 USA www.ingevity.com News Contact: Caroline Monahan 843-740-2068 [email protected] Investors: John E. Nypaver, Jr. 843-740-2002 [email protected] Ingevity reports third quarter 2024 financial results HIGHLIGHTS: •Net sales of $376.9 million, down 16% compared to prior year, primarily due to repositionin

Ingevity Corporation Fourth Amended and Restated Bylaws, effective October 22, 2024 (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K, as filed with the Commission on October 25, 2024).

Exhibit 3.2 THIRD FOURTH AMENDED AND RESTATED BYLAWS OF INGEVITY CORPORATION EFFECTIVE AS OF JULY 25, 2022 October 22, 2024 ARTICLE I MEETINGS OF STOCKHOLDERS Section 1.1 Place of Meetings. The annual meeting of stockholders for the election of directors and all special meetings for that or for any other purpose shall be held at such time and place, either within or without the State of Delaware a

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 October 22, 2024 Date of Report (date of earliest event reported) INGEVITY CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37586 47-4027764 (State or other jurisdiction of incorporation or organizatio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 October 2, 2024 Date of Report (date of earliest event reported) INGEVITY CORPORAT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 October 2, 2024 Date of Report (date of earliest event reported) INGEVITY CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37586 47-4027764 (State or other jurisdiction of incorporation or organization

Ingevity Corporation

Exhibit 99.1 Ingevity Corporation 4920 O’Hear Avenue Suite 400 North Charleston, S.C. 29405 USA www.ingevity.com Contact: News Caroline Monahan 843-740-2068 [email protected] Investors: John E. Nypaver, Jr. 843-740-2002 [email protected] Ingevity announces CEO transition as Fortson departs company; Fernandez-Moreno appointed as interim president and CEO NORTH CHARLESTON, S.C., Oct

July 3, 2024

Exhibit 10.3 July 3, 2024 Terry Dyer [Address] Dear Terry, We are pleased to provide written confirmation of our offer of employment with Ingevity Corporation (“Ingevity”) as Senior Vice President, Chief Human Resources Officer reporting to me based at our global headquarters in North Charleston, South Carolina, effective on a mutually agreeable 2024 date. Your compensation for this position will

[Signature Page Follows]

Exhibit 10.1 June 26, 2024 Stacy Cozad [Address] Dear Stacy: This transition agreement (this “Transition Agreement”) sets forth the terms and conditions related to the termination of your employment with Ingevity Corporation (“Ingevity” or the “Company”) as a result of your voluntary resignation, and contemplates you receiving certain Transition Benefits hereunder (as defined in paragraph 3, below

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37586 INGEVITY CORPORATION (Exact name of registrant as speci

SEVERANCE AND CHANGE OF CONTROL AGREEMENT

Exhibit 10.4 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. SUCH EXCLUDED INFORMATION IS DENOTED BY ASTERISKS IN BRACKETS [*****]. SEVERANCE AND CHANGE OF CONTROL AGREEMENT THIS SEVERANCE AND CHANGE OF CONTROL AGREEMENT (the “Agreement”) by and between Ingevity Corporation,

SEVERANCE AND CHANGE OF CONTROL AGREEMENT

Exhibit 10.6 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. SUCH EXCLUDED INFORMATION IS DENOTED BY ASTERISKS IN BRACKETS [*****]. SEVERANCE AND CHANGE OF CONTROL AGREEMENT THIS SEVERANCE AND CHANGE OF CONTROL AGREEMENT (the “Agreement”) by and between Ingevity Corporation,

July 3, 2024

Exhibit 10.5 July 3, 2024 Ryan Fisher [Address] Dear Ryan, We are pleased to provide written confirmation of our offer of employment with Ingevity Corporation (“Company”) as Senior Vice President, General Counsel and Corporate Secretary reporting to me based at our global headquarters in North Charleston, South Carolina, effective as of June 27, 2024. Your compensation for this position will be $3

Ingevity Corporation 4920 O'Hear Avenue Suite 400 North Charleston, SC 29405 USA www.ingevity.com News Contact: Caroline Monahan 843-740-2068 [email protected] Investors: John E. Nypaver, Jr. 843-740-2002 [email protected]

Exhibit 99.1 Ingevity Corporation 4920 O'Hear Avenue Suite 400 North Charleston, SC 29405 USA www.ingevity.com News Contact: Caroline Monahan 843-740-2068 [email protected] Investors: John E. Nypaver, Jr. 843-740-2002 [email protected] Ingevity announces additional steps to advance strategic repositioning and improve profitability of its Performance Chemicals segment •Will optimize existing

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 July 29, 2024 Date of Report (date of earliest event reported) INGEVITY CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37586 47-4027764 (State or other jurisdiction of incorporation or organization)

TABLE OF CONTENTS FINANCIAL SCHEDULES Page Condensed Consolidated Statements of Operations 1 Segment Operating Results 2 Condensed Consolidated Balance Sheets 4 Condensed Consolidated Statements of Cash Flows 5 Non-GAAP Financial Measures 6 Reconcili

Exhibit 99.1 Ingevity Corporation 4920 O'Hear Avenue Suite 400 North Charleston, SC 29405 USA www.ingevity.com News Contact: Caroline Monahan 843-740-2068 [email protected] Investors: John E. Nypaver, Jr. 843-740-2002 [email protected] Ingevity reports second quarter 2024 financial results HIGHLIGHTS: •Net sales of $390.6 million, down 19% compared to prior year •Net loss of $283.7 million a

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 July 31, 2024 Date of Report (date of earliest event reported) INGEVITY CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37586 47-4027764 (State or other jurisdiction of incorporation or organization)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 July 1, 2024 Date of Report (date of earliest event reported) INGEVITY CORPORATION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 July 1, 2024 Date of Report (date of earliest event reported) INGEVITY CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37586 47-4027764 (State or other jurisdiction of incorporation or organization) (

CONFIDENTIAL TERMINATION AGREEMENT AND RELEASE

Exhibit 10.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. SUCH EXCLUDED INFORMATION IS DENOTED BY ASTERISKS IN BRACKETS [*****]. CONFIDENTIAL TERMINATION AGREEMENT AND RELEASE This Confidential Termination Agreement and Release (“Agreement”) is made and executed as of Jul

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 June 26, 2024 Date of Report (date of earliest event reported) INGEVITY CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37586 47-4027764 (State or other jurisdiction of incorporation or organization)

Ingevity Corporation 4920 O'Hear Avenue, Suite 400 North Charleston, South Carolina 29405 843-740-2300

Ingevity Corporation 4920 O'Hear Avenue, Suite 400 North Charleston, South Carolina 29405 843-740-2300 June 20, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street N.

Ingevity Corporation 4920 O'Hear Avenue, Suite 400 North Charleston, South Carolina 29405 843-740-2300

Ingevity Corporation 4920 O'Hear Avenue, Suite 400 North Charleston, South Carolina 29405 843-740-2300 May 6, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street N.

Ingevity Corporation Third Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant’s Quarterly Report on Form 10-Q, as filed with the Commission on May 2, 2024).

Exhibit 3.1 THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF INGEVITY CORPORATION The present name of the corporation is Ingevity Corporation. The corporation was incorporated under the name MWV CATALYST SPINCO, INC. on March 27, 2015 by the filing of its original Certificate of Incorporation with the Secretary of State of the State of Delaware. This Third Amended and Restated Certificat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37586 INGEVITY CORPORATION (Exact name of registrant as spec

TABLE OF CONTENTS FINANCIAL SCHEDULES Page Condensed Consolidated Statements of Operations 1 Segment Operating Results 2 Condensed Consolidated Balance Sheets 3 Condensed Consolidated Statements of Cash Flows 4 Non-GAAP Financial Measures 5 Reconcili

Exhibit 99.1 Ingevity Corporation 4920 O'Hear Avenue Suite 400 North Charleston, SC 29405 USA www.ingevity.com News Contact: Caroline Monahan 843-740-2068 [email protected] Investors: John E. Nypaver, Jr. 843-740-2002 [email protected] Ingevity reports first quarter 2024 financial results HIGHLIGHTS: (comparisons versus prior year period) •Net sales of $340.1 million, down 13% primarily as a

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 May 1, 2024 Date of Report (date of earliest event reported) INGEVITY CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37586 47-4027764 (State or other jurisdiction of incorporation or organization) (C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 April 23, 2024 Date of Report (date of earliest event reported) INGEVITY CORPORATI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 April 23, 2024 Date of Report (date of earliest event reported) INGEVITY CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37586 47-4027764 (State or other jurisdiction of incorporation or organization)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Pro

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 March 12, 2024 Date of Report (date of earliest event reported) INGEVITY CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37586 47-4027764 (State or other jurisdiction of incorporation or organization)

NOTICE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.

COURTESY PDF OF PROXY STATEMENT

MESSAGE FROM OUR CEO John C. Fortson | March 11, 2024 Dear Ingevity Stockholders: It is our pleasure to invite you to attend the 2024 annual meeting of stockholders (the “Annual Meeting”) of Ingevity Corporation ("Ingevity," the “Company” or "us"). The Annual Meeting will be held virtually via live audio webcast on April 23, 2024, at 9:30 a.m. Eastern Time. You can participate in the Annual Meetin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.

NOTICE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.

NGVT / Ingevity Corporation / INCLUSIVE CAPITAL PARTNERS, L.P. - INGEVITY CORP Activist Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Ingevity Corporation (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 45688C107 (CUSIP Number) Philippe B. Pradel Inclusive Capital Partners, L.P. 1170 Gorgas Avenue San Francisco, CA 94129 Eleazer Klein, Esq. Adriana Schwartz,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37586 INGEVITY CORPORATION (Exact name of registrant as specified

Senior Executive Recoupment Policy Acknowledgment Form

Exhibit 97.1 Policy Name: Senior Executive Recoupment Policy Department/Group: Law and Compliance Policy Scope Covered Officers (as defined below) Effective Date July 24, 2023 Pages Page 1 of 4 I.PURPOSE The Board of Directors of Ingevity Corporation (the “Company”) hereby adopts this policy (the “Policy”) providing for the Company’s ability to recoup some or all of the incentive compensation paid

INGEVITY CORPORATION SUBSIDIARIES OF THE REGISTRANT Name of Subsidiary Jurisdiction of Organization Ingevity Corporation Delaware, United States of America Ingevity South Carolina, LLC Delaware, United States of America Ingevity Virginia Corporation

Exhibit 21.1 INGEVITY CORPORATION SUBSIDIARIES OF THE REGISTRANT Name of Subsidiary Jurisdiction of Organization Ingevity Corporation Delaware, United States of America Ingevity South Carolina, LLC Delaware, United States of America Ingevity Virginia Corporation Virginia, United States of America Ingevity Arkansas, LLC Delaware, United States of America Ingevity Services, Inc. Delaware, United Sta

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 February 21, 2024 Date of Report (date of earliest event reported) INGEVITY CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37586 47-4027764 (State or other jurisdiction of incorporation or organizati

TABLE OF CONTENTS FINANCIAL SCHEDULES Page Condensed Consolidated Statements of Operations 1 Segment Operating Results 2 Condensed Consolidated Balance Sheets 4 Condensed Consolidated Statements of Cash Flows 5 Non-GAAP Financial Measures 6 Reconcili

Exhibit 99.1 Ingevity Corporation 4920 O'Hear Avenue Suite 400 North Charleston, SC 29405 USA www.ingevity.com News Contact: Caroline Monahan 843-740-2068 [email protected] Investors: John Nypaver 843-740-2002 [email protected] Ingevity reports fourth quarter and full year 2023 financial results Fourth Quarter (comparisons versus prior year period): •Net sales of $371.7 million decreased 3.1

NGVT / Ingevity Corporation / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 10)* Name of issuer: Ingevity Corp Title of Class of Securities: Common Stock CUSIP Number: 45688C107 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule

NGVT / Ingevity Corporation / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment

SC 13G 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* INGEVITY CORPORATION (Name of Issuer) Common Stock (Title of Class of Securities) 45688C107 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to de

NGVT / Ingevity Corporation / VICTORY CAPITAL MANAGEMENT INC Passive Investment

SC 13G 1 ingevitycorp13g123123.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Ingevity Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 45688C107 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the ru

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37586 INGEVITY CORPORATION (Exact name of registrant as

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 November 1, 2023 Date of Report (date of earliest event reported) INGEVITY CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37586 47-4027764 (State or other jurisdiction of incorporation or organizatio

Ingevity Corporation 4920 O'Hear Avenue Suite 400 North Charleston, SC 29405 USA www.ingevity.com News Contact: Caroline Monahan 843-740-2068 [email protected] Investors: John E. Nypaver, Jr. 843-740-2002 [email protected]

Exhibit 99.1 Ingevity Corporation 4920 O'Hear Avenue Suite 400 North Charleston, SC 29405 USA www.ingevity.com News Contact: Caroline Monahan 843-740-2068 [email protected] Investors: John E. Nypaver, Jr. 843-740-2002 [email protected] Ingevity announces further repositioning of its Performance Chemicals business, including the closure of its DeRidder, Louisiana facility, and additional comp

TABLE OF CONTENTS FINANCIAL SCHEDULES Page Condensed Consolidated Statements of Operations 1 Segment Operating Results 2 Condensed Consolidated Balance Sheets 3 Condensed Consolidated Statements of Cash Flows 4 Non-GAAP Financial Measures 5 Reconcili

Exhibit 99.1 Ingevity Corporation 4920 O'Hear Avenue Suite 400 North Charleston, SC 29405 USA www.ingevity.com News Contact: Caroline Monahan 843-740-2068 [email protected] Investors: John E. Nypaver, Jr. 843-740-2002 [email protected] Ingevity reports third quarter 2023 financial results HIGHLIGHTS: (comparisons versus prior year period) •Net sales of $446.0 million, down 7%, compared to a

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 October 30, 2023 Date of Report (date of earliest event reported) INGEVITY CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37586 47-4027764 (State or other jurisdiction of incorporation or organizatio

BLACK LIQUOR SOAP SKIMMINGS AGREEMENT

Exhibit 10.1 AMENDMENT NO.1 TO THE AMENDED AND RESTATED CRUDE TALL OIL AND BLACK LIQUOR SOAP SKIMMINGS AGREEMENT This Amendment No.1 (this “Amendment”) to the Amended and Restated Crude Tall Oil and Black Liquor Soap Skimmings Agreement, is made and entered into as of November 1, 2023 (the “Amendment Effective Date”), by and between WestRock Shared Services, LLC and WestRock MWV, LLC, on behalf of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37586 INGEVITY CORPORATION (Exact name of registrant as speci

TERMS AND CONDITIONS

Exhibit 10.1 Ingevity Corporation Restricted Stock Unit Awards (Performance Chemicals Transformation Award Tier I Commercial - Performance-Based) CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) IS THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. SUCH EXCLUDED INFORMATION IS DENOTED BY ASTERISKS IN BRACKETS [*****]. TERMS A

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 August 2, 2023 Date of Report (date of earliest event reported) INGEVITY CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37586 47-4027764 (State or other jurisdiction of incorporation or organization)

TABLE OF CONTENTS FINANCIAL SCHEDULES Page Condensed Consolidated Statements of Operations 1 Segment Operating Results 2 Condensed Consolidated Balance Sheets 3 Condensed Consolidated Statements of Cash Flows 4 Non-GAAP Financial Measures 5 Reconcili

Exhibit 99.1 Ingevity Corporation 4920 O'Hear Avenue Suite 400 North Charleston, SC 29406 USA www.ingevity.com News Contact: Caroline Monahan 843-740-2068 [email protected] Investors: John E. Nypaver, Jr. 843-740-2002 [email protected] Ingevity reports second quarter 2023 financial results HIGHLIGHTS: (comparisons versus prior year period) •Net sales of $481.8 million, up 15% •Net income of

NGVT / Ingevity Corp / INCLUSIVE CAPITAL PARTNERS, L.P. - INGEVITY CORP Activist Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Ingevity Corporation (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 45688C107 (CUSIP Number) Philippe B. Pradel Inclusive Capital Partners, L.P. 1170 Gorgas Avenue San Francisco, CA 94129 Eleazer Klein, Esq. Adriana Schwartz,

Calculation of Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Table Form S-8 Ingevity Corporation Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price (2) Fee Rate Amount of Registration Fee Equity Common stock, par value $0.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933 INGEVITY CORPORATION (Exact name of registrant as specified in its charter)

As filed with the Securities and Exchange Commission on May 4, 2023 Registration No.

[Signature page follows]

EX-10.1 February 27, 2023 Erik Ripple [Address] Dear Erik: This letter is written to set forth the terms and conditions for termination of your employment with Ingevity Corporation (“Ingevity” or the “Company”). *** INGEVITY AND THE EMPLOYEE AGREE: THIS AGREEMENT IS SUBJECT TO BINDING ARBITRATION UNDER THE FEDERAL ARBITRATION ACT ("FAA"). HOWEVER, TO THE EXTENT THE FAA IS FOUND TO BE INAPPLICABLE,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37586 INGEVITY CORPORATION (Exact name of registrant as spec

Amended and Restated 2017 Ingevity Corporation Employee Stock Purchase Plan.

Exhibit 10.1 Amended and Restated 2017 INGEVITY CORPORATION EMPLOYEE STOCK PURCHASE PLAN 1. Purpose The purpose of the Plan is to provide Eligible Employees of Ingevity and each of its Designated Subsidiaries with the opportunity to purchase Stock in Ingevity through payroll deduction, thereby encouraging employees to share in the economic growth and success of the company through Stock ownership.

TABLE OF CONTENTS FINANCIAL SCHEDULES Page Condensed Consolidated Statements of Operations 1 Segment Operating Results 2 Condensed Consolidated Balance Sheets 3 Condensed Consolidated Statements of Cash Flows 4 Non-GAAP Financial Measures 5 Reconcili

Exhibit 99.1 Ingevity Corporation 4920 O'Hear Avenue Suite 400 North Charleston, SC 29406 USA www.ingevity.com News Contact: Caroline Monahan 843-740-2068 [email protected] Investors: John Nypaver 843-740-2002 [email protected] Ingevity reports first quarter 2023 financial results HIGHLIGHTS: (comparisons versus prior year period) •Net sales of $392.6 million, up 2.6% •Net income of $50.7 mi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 May 3, 2023 Date of Report (date of earliest event reported) INGEVITY CORPORATION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 May 3, 2023 Date of Report (date of earliest event reported) INGEVITY CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37586 47-4027764 (State or other jurisdiction of incorporation or organization) (C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 April 27, 2023 Date of Report (date of earliest event reported) INGEVITY CORPORATI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 April 27, 2023 Date of Report (date of earliest event reported) INGEVITY CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37586 47-4027764 (State or other jurisdiction of incorporation or organization)

Second Amendment to Crude Tall Oil Supply Agreement, dated March 21, 2023, by and between Georgia-Pacific LLC, on behalf of itself and its subsidiaries, GP Pine Chemicals LLC and Ingevity Corporation*

Exhibit 10.2 Second Amendment to Crude Tall Oil Supply Agreement This Second Amendment (this “Second Amendment”) to the Crude Tall Oil Supply Agreement, made effective as of March 1, 2023 (“Amendment Effective Date”) is entered into by and between Georgia-Pacific LLC, a Delaware limited liability company, on behalf of itself and its subsidiaries (“Seller”) and Ingevity Corporation, a Delaware corp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 20, 2023 Date of Report (date of earliest event reported) INGEVITY CORPORATIO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 20, 2023 Date of Report (date of earliest event reported) INGEVITY CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37586 47-4027764 (State or other jurisdiction of incorporation or organization)

Amended and Restated Crude Tall Oil and Black Liquor Soap Skimmings Agreement, dated March 20, 2023, by and between WestRock Shared Services, LLC and WestRock MWV, LLC, on behalf of the affiliates of WestRock Company, and Ingevity Corporation*

Exhibit 10.1 AMENDED AND RESTATED CRUDE TALL OIL AND BLACK LIQUOR SOAP SKIMMINGS AGREEMENT THIS AMENDED AND RESTATED CRUDE TALL OIL AND BLACK LIQUOR SOAP SKIMMINGS AGREEMENT (this “Agreement”) is made and entered into on March 20, 2023, (“Effective Date”), by and between WestRock Shared Services, LLC and WestRock MWV, LLC, on behalf of the affiliates of WestRock Company (“Seller”), and Ingevity Co

TABLE OF CONTENTS

Exhibit 99.1 TABLE OF CONTENTS FINANCIAL SCHEDULES Page Recasted Segment Operating Results 2022 Quarters and Full Year 1 2021 Quarters and Full Year 2 2020 Quarters and Full Year 3 INGEVITY CORPORATION Recasted 2022 Segment Operating Results (Unaudited) 2022 In millions Q1 Q2 Q3 Q4 FY Net sales Performance Materials $ 148.4 $ 122.4 $ 144.9 $ 132.8 $ 548.5 Performance Chemicals 172.6 243.7 267.6 19

COURTESY PDF OF PROXY STATEMENT

1 INGEVITY | 2023 Proxy Statement MESSAGE FROM OUR CEO John C. Fortson | March 10, 2023 Dear Ingevity Stockholders: It is our pleasure to invite you to attend the 2023 annual meeting of stockholders (the “Annual Meeting”) of Ingevity Corporation (the “Company”). The Annual Meeting will be held virtually via live audio webcast on April 27, 2023, at 9:30 a.m. Eastern Time. You can participate in the

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.

MESSAGE FROM OUR CEO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549f SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.

INGEVITY CORPORATION SUBSIDIARIES OF THE REGISTRANT Name of Subsidiary Jurisdiction of Organization Ingevity Corporation Delaware, United States of America Ingevity South Carolina, LLC Delaware, United States of America Ingevity Virginia Corporation

Exhibit 21.1 INGEVITY CORPORATION SUBSIDIARIES OF THE REGISTRANT Name of Subsidiary Jurisdiction of Organization Ingevity Corporation Delaware, United States of America Ingevity South Carolina, LLC Delaware, United States of America Ingevity Virginia Corporation Virginia, United States of America Ingevity Arkansas, LLC Delaware, United States of America Ingevity Services, Inc. Delaware, United Sta

Exhibit 4.3

Exhibit 4.3 DESCRIPTION OF THE REGISTRANT'S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Ingevity Corporation has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our Common Stock. The following description of our Common Stock is a summary and is qualified in its entirety by reference to our certificate o

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37586 INGEVITY CORPORATION (Exact name of registrant as specified

The results and guidance in this release include non-GAAP financial measures. Refer to the section entitled “Use of non-GAAP financial measures” within this release.

Exhibit 99.1 Ingevity Corporation 4920 O'Hear Avenue Suite 400 North Charleston, SC 29405 USA www.ingevity.com News Contact: Caroline Monahan 843-740-2068 [email protected] Investors: John Nypaver 843-740-2002 [email protected] Ingevity reports fourth quarter and full year 2022 financial results Highlights: Full year 2022 was a record year for both net sales and EBITDA, driven by growth acro

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 February 27, 2023 Date of Report (date of earliest event reported) INGEVITY CORPOR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 February 27, 2023 Date of Report (date of earliest event reported) INGEVITY CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37586 47-4027764 (State or other jurisdiction of incorporation or organizati

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 February 16, 2023 Date of Report (date of earliest event reported) INGEVITY CORPOR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 February 16, 2023 Date of Report (date of earliest event reported) INGEVITY CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37586 47-4027764 (State or other jurisdiction of incorporation or organizati

Ingevity Corporation 4920 O'Hear Avenue Suite 400 North Charleston, SC 29406 USA www.ingevity.com News Contact: Caroline Monahan 843-740-2068 [email protected] Investors: John Nypaver 843-740-2002 [email protected]

Exhibit 99.1 Ingevity Corporation 4920 O'Hear Avenue Suite 400 North Charleston, SC 29406 USA www.ingevity.com News Contact: Caroline Monahan 843-740-2068 [email protected] Investors: John Nypaver 843-740-2002 [email protected] Ingevity elects new member to its Board of Directors NORTH CHARLESTON, S.C., Feb. 21, 2023 – Ingevity Corporation (NYSE:NGVT) today announced the election of Bruce Ho

NGVT / Ingevity Corp / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)* Name of issuer: Ingevity Corp. Title of Class of Securities: Common Stock CUSIP Number: 45688C107 Date of Event Which Requires Filing of this Statement: January 31, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule

NGVT / Ingevity Corp / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv01143-ingevitycorp.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8)* Name of issuer: Ingevity Corp. Title of Class of Securities: Common Stock CUSIP Number: 45688C107 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the ru

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37586 INGEVITY CORPORATION (Exact name of registrant as

TABLE OF CONTENTS FINANCIAL SCHEDULES Page Condensed Consolidated Statements of Operations 1 Segment Operating Results 2 Condensed Consolidated Balance Sheets 3 Condensed Consolidated Statements of Cash Flows 4 Non-GAAP Financial Measures 5 Reconcili

Exhibit 99.1 Ingevity Corporation 4920 O'Hear Avenue Suite 400 North Charleston, SC 29406 USA www.ingevity.com News Contact: Caroline Monahan 843-740-2068 [email protected] Investors: John Nypaver 843-740-2002 [email protected] Ingevity reports third quarter 2022 financial results HIGHLIGHTS: (comparisons versus prior year period) ?Company delivered record sales of $482.0 million, up 27.9% ?

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 November 2, 2022 Date of Report (date of earliest event reported) INGEVITY CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37586 47-4027764 (State or other jurisdiction of incorporation or organizatio

Ingevity Corporation 4920 O'Hear Avenue Suite 400 North Charleston, SC 29405 USA www.ingevity.com News Contact: Caroline Monahan 843-740-2068 [email protected] Investors: John Nypaver 843-740-2002 [email protected]

Exhibit 99.1 Ingevity Corporation 4920 O'Hear Avenue Suite 400 North Charleston, SC 29405 USA www.ingevity.com News Contact: Caroline Monahan 843-740-2068 [email protected] Investors: John Nypaver 843-740-2002 [email protected] Ingevity completes acquisition of leading pavement marking materials business, Ozark Materials NORTH CHARLESTON, S.C., Oct. 3, 2022 ? Ingevity Corporation

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 October 3, 2022 Date of Report (date of earliest event reported) INGEVITY CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37586 47-4027764 (State or other jurisdiction of incorporation or organization

AMENDED AND RESTATED SEVERANCE AND CHANGE OF CONTROL AGREEMENT

Exhibit 10.3 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) IS THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. SUCH EXCLUDED INFORMATION IS DENOTED BY ASTERISKS IN BRACKETS [*****]. AMENDED AND RESTATED SEVERANCE AND CHANGE OF CONTROL AGREEMENT THIS AMENDED AND RESTATED SEVERANCE AND CHANGE OF CONTROL AGREEMENT (the ?Agr

April 27, 2022

Exhibit 10.1 April 27, 2022 Christine Stunyo [Address] Dear Christine, We are pleased to provide written confirmation of our offer of employment with Ingevity Corporation (?Ingevity?) as Senior Vice President, Chief Human Resources Officer reporting to me based at our global headquarters in North Charleston, South Carolina, effective on a mutually agreeable 2022 date. Your compensation for this po

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT PURSUANT TO S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37586 INGEVITY CORPORATION (Exact name of registrant as speci

SEVERANCE AND CHANGE OF CONTROL AGREEMENT

Exhibit 10.2 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) IS THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. SUCH EXCLUDED INFORMATION IS DENOTED BY ASTERISKS IN BRACKETS [*****]. SEVERANCE AND CHANGE OF CONTROL AGREEMENT THIS SEVERANCE AND CHANGE OF CONTROL AGREEMENT (the ?Agreement?) by and between Ingevity Corporati

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 31, 2022 Date of Report (date of earliest event reported) INGEVITY CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37586 47-4027764 (State or other jurisdiction of incorporation or organization) (

Equity Purchase Agreement, dated July 31, 2022, by and among Ingevity Corporation, Ozark Holdings, Inc., Ozark Materials, LLC and Ozark Logistics, LLC*

Exhibit 2.1 EXECUTION VERSION EQUITY PURCHASE AGREEMENT BY AND AMONG INGEVITY CORPORATION, OZARK HOLDINGS, INC., OZARK MATERIALS, LLC AND OZARK LOGISTICS, LLC Dated as of July 31, 2022 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 ARTICLE II PURCHASE AND SALE OF INTERESTS 15 Section 2.1 Basic Transaction 15 Section 2.2 Closing Payments 15 Section 2.3 Closing 15 Section 2.4 Deliveries at Closing 1

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 August 2, 2022 Date of Report (date of earliest event reported) INGEVITY CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37586 47-4027764 (State or other jurisdiction of incorporation or organization)

Transaction Support Agreement, dated July 31, 2022, by and among Ingevity Corporation, William H. Carr, Jerry N. Carr, Leon M. Gross, III, Ozark Holdings, Inc. and each of the other entities that are signatories thereto*

Exhibit 10.1 EXECUTION VERSION TRANSACTION SUPPORT AGREEMENT This Transaction Support Agreement (this “Agreement”), dated as of July 31, 2022, is made by and among Ingevity Corporation, a Delaware corporation (“Buyer”), William H. Carr, an individual resident of Alabama (“Bill Carr”), Jerry N. Carr, an individual resident of Florida (“Jerry Carr”), Leon M. Gross, III, an individual resident of Ala

Ingevity to acquire leading pavement marking materials business, Ozark Materials

Exhibit 99.1 Ingevity to acquire leading pavement marking materials business, Ozark Materials NORTH CHARLESTON, S.C., August 2, 2022 – Ingevity Corporation (NYSE:NGVT) today announced it has reached an agreement to acquire privately-owned Ozark Materials, LLC and Ozark Logistics, LLC (“Ozark Materials”) in an all-cash transaction valued at $325 million. The acquisition is subject to regulatory app

TABLE OF CONTENTS FINANCIAL SCHEDULES Page Condensed Consolidated Statements of Operations 1 Segment Operating Results 2 Condensed Consolidated Balance Sheets 3 Condensed Consolidated Statements of Cash Flows 4 Non-GAAP Financial Measures 5 Reconcili

Exhibit 99.1 Ingevity Corporation 4920 O'Hear Avenue Suite 400 North Charleston, SC 29406 USA www.ingevity.com News Contact: Caroline Monahan 843-740-2068 [email protected] Investors: John Nypaver 843-740-2002 [email protected] Ingevity reports second quarter 2022 financial results HIGHLIGHTS: (comparisons versus prior year period) •Company delivered record sales of $419.9 million, up 17.2%

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 July 25, 2022 Date of Report (date of earliest event reported) INGEVITY CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37586 47-4027764 (State or other jurisdiction of incorporation or organization)

NGVT / Ingevity Corp / INCLUSIVE CAPITAL PARTNERS, L.P. - INGEVITY CORPORATION Activist Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Ingevity Corporation (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 45688C107 (CUSIP Number) Philippe B. Pradel Inclusive Capital Partners, L.P. 1170 Gorgas Avenue San Francisco, CA 94129 Eleazer Klein, Esq. Adriana Schwartz,

Ingevity Corporation 4920 O'Hear Avenue Suite 400 North Charleston, SC 29406 USA www.ingevity.com News Contact: Caroline Monahan 843-740-2068 [email protected] Investors: John Nypaver 843-740-2002 [email protected]

Exhibit 99.1 Ingevity Corporation 4920 O'Hear Avenue Suite 400 North Charleston, SC 29406 USA www.ingevity.com News Contact: Caroline Monahan 843-740-2068 [email protected] Investors: John Nypaver 843-740-2002 [email protected] Ingevity announces changes to its Board of Directors NORTH CHARLESTON, S.C., July 27, 2022 ? Ingevity Corporation (NYSE:NGVT) today announced the election of William

Ingevity Corporation Third Amended and Restated Bylaws, effective July 25, 2022 (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K, as filed with the Commission on July 27, 2022).

Exhibit 3.2 THIRD AMENDED AND RESTATED BYLAWS OF INGEVITY CORPORATION EFFECTIVE AS OF JULY 25, 2022 ARTICLE I MEETINGS OF STOCKHOLDERS Section 1.1 Place of Meetings. The annual meeting of stockholders for the election of directors and all special meetings for that or for any other purpose shall be held at such time and place, either within or without the State of Delaware as may from time to time

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 23, 2022 Date of Report (date of earliest event reported) INGEVITY CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37586 47-4027764 (State or other jurisdiction of incorporation or organization) (

Amendment and Restatement Agreement, dated as of June 23, 2022, among Ingevity Corporation, Ingevity Holdings SRL, Ingevity UK Ltd, the other loan parties party thereto, JPMorgan Chase Bank, N.A., as the administrative agent, and the lenders party thereto

Exhibit 10.1 Execution Version AMENDMENT AND RESTATEMENT AGREEMENT AMENDMENT AND RESTATEMENT AGREEMENT, dated as of June 23, 2022 (this ?Amendment?), among INGEVITY CORPORATION, a Delaware corporation (the ?U.S. Borrower?), INGEVITY HOLDINGS SRL (formerly MEADWESTVACO EUROPE SPRL), a Belgian private limited liability company (soci?t? ? responsabilit? limit?e/besloten vennootschap) incorporated und

Terms and Conditions

Exhibit 10.2 July 1, 2021 Dear Steven, One of my most important responsibilities as CEO is to ensure Ingevity attracts, develops and retains the leadership talent necessary for long-term success. To do so, it is imperative that we recognize and reward outstanding performance. In recognition of your past and current contributions, and in expectation of the value you will bring to Ingevity going for

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ☐ TRANSITION REPORT PURSUANT TO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37586 INGEVITY CORPORATION (Exact name of registrant as spec

TABLE OF CONTENTS FINANCIAL SCHEDULES Page Condensed Consolidated Statements of Operations 1 Segment Operating Results 2 Condensed Consolidated Balance Sheets 3 Condensed Consolidated Statements of Cash Flows 4 Non-GAAP Financial Measures 5 Reconcili

Exhibit 99.1 Ingevity Corporation 4920 O'Hear Avenue Suite 400 North Charleston, SC 29406 USA www.ingevity.com News Contact: Caroline Monahan 843-740-2068 [email protected] Investors: John Nypaver 843-740-2002 [email protected] Ingevity reports first quarter 2022 financial results HIGHLIGHTS: (comparisons versus prior year) ?Company delivered strong results driven by record sales of $382.8 m

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 May 4, 2022 Date of Report (date of earliest event reported) INGEVITY CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37586 47-4027764 (State or other jurisdiction of incorporation or organization) (C

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 April 27, 2022 Date of Report (date of earliest event reported) INGEVITY CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37586 47-4027764 (State or other jurisdiction of incorporation or organization)

NGVT / Ingevity Corp / INCLUSIVE CAPITAL PARTNERS, L.P. - INGEVITY CORPORATION Activist Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Ingevity Corporation (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 45688C107 (CUSIP Number) Philippe B. Pradel Inclusive Capital Partners, L.P. 1170 Gorgas Avenue San Francisco, CA 94129 Eleazer Klein, Esq. Adriana Schwartz, Es

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

COURTESY PDF

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

Terms and Conditions

Exhibit 10.47 Ingevity Corporation Form of Restricted Stock Unit Award for U.K. Employees (Service-Based ? Three-Year Cliff Vesting) Under the 2016 Omnibus Incentive Plan, as Amended [Award Form First Used in 2022] Terms and Conditions 1.Terms and Conditions: This grant of service-based restricted stock units is made under the Ingevity Corporation 2016 Omnibus Incentive Plan (the ?Plan?), and is s

1

Exhibit 10.39 December 2, 2021 Steven Hulme [Address] Dear Steve, We are pleased to provide written confirmation of our offer of employment with Ingevity Corporation (?Company?) as Senior Vice President, Performance Chemicals and President, Engineered Polymers reporting to me based at our Warrington, England location, effective January 1, 2022. All your terms and conditions of employment remain un

Terms and Conditions

Exhibit 10.48 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD BE LIKELY TO CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. SUCH EXCLUDED INFORMATION IS DENOTED BY ASTERISKS IN BRACKETS [*****]. Ingevity Corporation Form of Cash Award for International Participants (Performance-Based) Under the 2016 Omnibus Incentive

AMENDED AND RESTATED SEVERANCE AND CHANGE OF CONTROL AGREEMENT

Exhibit 10.51 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD BE LIKELY TO CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. SUCH EXCLUDED INFORMATION IS DENOTED BY ASTERISKS IN BRACKETS [*****]. AMENDED AND RESTATED SEVERANCE AND CHANGE OF CONTROL AGREEMENT THIS AMENDED AND RESTATED SEVERANCE AND CHANGE OF CONTROL AG

TERMS AND CONDITIONS

Exhibit 10.42 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD BE LIKELY TO CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. SUCH EXCLUDED INFORMATION IS DENOTED BY ASTERISKS IN BRACKETS [*****]. Ingevity Corporation Form of Restricted Stock Unit Award for U.S. Employees (Performance-Based) Under the 2016 Omnibus Ince

TERMS AND CONDITIONS

Exhibit 10.43 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD BE LIKELY TO CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. SUCH EXCLUDED INFORMATION IS DENOTED BY ASTERISKS IN BRACKETS [*****]. Ingevity Corporation Form of Restricted Stock Unit Award for U.K. Employees (Performance-Based) Under the 2016 Omnibus Ince

Terms and Conditions

Exhibit 10.44 Ingevity Corporation Form of Restricted Stock Unit Award for U.S. Employees (Service-Based ? Three-Year Ratable Vesting) Under the 2016 Omnibus Incentive Plan, as Amended [Award Form First Used in 2021] Terms and Conditions 1.Terms and Conditions: This grant of service-based restricted stock units is made under the Ingevity Corporation 2016 Omnibus Incentive Plan (the ?Plan?), and is

AMENDED AND RESTATED SEVERANCE AND CHANGE OF CONTROL AGREEMENT

Exhibit 10.50 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD BE LIKELY TO CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. SUCH EXCLUDED INFORMATION IS DENOTED BY ASTERISKS IN BRACKETS [*****]. AMENDED AND RESTATED SEVERANCE AND CHANGE OF CONTROL AGREEMENT THIS AMENDED AND RESTATED SEVERANCE AND CHANGE OF CONTROL AG

AMENDED AND RESTATED SEVERANCE AND CHANGE OF CONTROL AGREEMENT

Exhibit 10.53 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD BE LIKELY TO CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. SUCH EXCLUDED INFORMATION IS DENOTED BY ASTERISKS IN BRACKETS [*****]. AMENDED AND RESTATED SEVERANCE AND CHANGE OF CONTROL AGREEMENT THIS AMENDED AND RESTATED SEVERANCE AND CHANGE OF CONTROL AG

SEVERANCE AND CHANGE OF CONTROL AGREEMENT

Exhibit 10.33 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD BE LIKELY TO CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. SUCH EXCLUDED INFORMATION IS DENOTED BY ASTERISKS IN BRACKETS [*****]. SEVERANCE AND CHANGE OF CONTROL AGREEMENT THIS SEVERANCE AND CHANGE OF CONTROL AGREEMENT (the ?Agreement?) by and between I

Terms and Conditions

Exhibit 10.40 Ingevity Corporation Form of Stock Option Award for U.S. Employees Under the 2016 Omnibus Incentive Plan, as Amended [Award Form First Used in 2021] Terms and Conditions 1.Terms and Conditions: This grant of stock options (the ?Option Award?) is made under Ingevity Corporation 2016 Omnibus Incentive Plan, (the ?Plan?), and is subject in all respects to the terms of the Plan. All term

1

Exhibit 10.38 December 2, 2021 Rich White [Address] Dear Rich, We are pleased to provide written confirmation of our offer of employment with Ingevity Corporation (?Company?) as Senior Vice President, Performance Chemicals and President, Industrial Specialties and Pavement Technologies reporting to me based at our global headquarters in North Charleston, South Carolina, effective January 1, 2022.

INGEVITY CORPORATION SUBSIDIARIES OF THE REGISTRANT Name of Subsidiary Jurisdiction of Organization Ingevity Corporation Delaware, United States of America Ingevity South Carolina, LLC Delaware, United States of America Ingevity Virginia Corporation

Exhibit 21.1 INGEVITY CORPORATION SUBSIDIARIES OF THE REGISTRANT Name of Subsidiary Jurisdiction of Organization Ingevity Corporation Delaware, United States of America Ingevity South Carolina, LLC Delaware, United States of America Ingevity Virginia Corporation Virginia, United States of America Ingevity Arkansas, LLC Delaware, United States of America Ingevity Services, Inc. Delaware, United Sta

DESCRIPTION OF THE REGISTRANT'S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934

Exhibit 4.3 DESCRIPTION OF THE REGISTRANT'S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Ingevity Corporation has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our Common Stock. The following description of our Common Stock is a summary and is qualified in its entirety by reference to our certificate o

Terms and Conditions

Exhibit 10.45 Ingevity Corporation Form of Restricted Stock Unit Award for U.K. Employees (Service-Based ? Three-Year Ratable Vesting) Under the 2016 Omnibus Incentive Plan, as Amended [Award Form First Used in 2022] Terms and Conditions 1.Terms and Conditions: This grant of service-based restricted stock units is made under the Ingevity Corporation 2016 Omnibus Incentive Plan (the ?Plan?), and is

1

Exhibit 10.37 January 5, 2021 Stacy Cozad [Address] Dear Stacy, We are pleased to provide written confirmation of our offer of employment with Ingevity Corporation (?Ingevity?) as Executive Vice President, General Counsel and Secretary reporting to me based at our global headquarters in North Charleston, South Carolina, effective on a mutually agreeable 2021 date. Your compensation for this positi

Terms and Conditions

Exhibit 10.41 Ingevity Corporation Form of Stock Option Award for U.K. Employees Under the 2016 Omnibus Incentive Plan, as Amended [Award Form First Used in 2022] Terms and Conditions 1.Terms and Conditions: This grant of stock options (the ?Option Award?) is made under Ingevity Corporation 2016 Omnibus Incentive Plan, (the ?Plan?), and is subject in all respects to the terms of the Plan. All term

Terms and Conditions

Exhibit 10.49 Ingevity Corporation Form of Cash Award for International Participants (Service-Based Cash ? Three-Year Ratable Vesting) Under the 2016 Omnibus Incentive Plan, as Amended Terms and Conditions 1.Terms and Conditions: This service-based cash award is made under the Ingevity Corporation 2016 Omnibus Incentive Plan (the ?Plan?), and is subject in all respects to the terms of the Plan. Al

AMENDED AND RESTATED SEVERANCE AND CHANGE OF CONTROL AGREEMENT

Exhibit 10.54 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD BE LIKELY TO CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. SUCH EXCLUDED INFORMATION IS DENOTED BY ASTERISKS IN BRACKETS [*****]. AMENDED AND RESTATED SEVERANCE AND CHANGE OF CONTROL AGREEMENT THIS AMENDED AND RESTATED SEVERANCE AND CHANGE OF CONTROL AG

AMENDED AND RESTATED SEVERANCE AND CHANGE OF CONTROL AGREEMENT

Exhibit 10.52 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD BE LIKELY TO CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. SUCH EXCLUDED INFORMATION IS DENOTED BY ASTERISKS IN BRACKETS [*****]. AMENDED AND RESTATED SEVERANCE AND CHANGE OF CONTROL AGREEMENT THIS AMENDED AND RESTATED SEVERANCE AND CHANGE OF CONTROL AG

1

Exhibit 10.36 March 17, 2021 Mary Dean Hall [Address] Dear Mary, We are pleased to provide written confirmation of our offer of employment with Ingevity Corporation (?Ingevity?) as Executive Vice President and Chief Financial Officer reporting to me based at our global headquarters in North Charleston, South Carolina, effective on a mutually agreeable 2021 date. Your compensation for this position

1

Exhibit 10.35 August 21, 2020 John C. Fortson [Address] Dear John, We are pleased to provide written confirmation of our offer of employment with Ingevity Corporation (?Ingevity?) as President and Chief Executive Officer reporting to Ingevity?s Board of Directors based at our global headquarters in North Charleston, South Carolina, effective September 1, 2020. Additionally, should you accept this

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37586 INGEVITY CORPORATION (Exact name of registrant as specified

SEVERANCE AND CHANGE OF CONTROL AGREEMENT

Exhibit 10.34 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD BE LIKELY TO CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. SUCH EXCLUDED INFORMATION IS DENOTED BY ASTERISKS IN BRACKETS [*****]. SEVERANCE AND CHANGE OF CONTROL AGREEMENT THIS SEVERANCE AND CHANGE OF CONTROL AGREEMENT (the ?Agreement?) by and between I

Terms and Conditions

Exhibit 10.46 Ingevity Corporation Form of Restricted Stock Unit Award for U.S. Employees (Service-Based ? Three-Year Cliff Vesting) Under the 2016 Omnibus Incentive Plan, as Amended [Award Form First Used in 2021] Terms and Conditions 1.Terms and Conditions: This grant of service-based restricted stock units is made under the Ingevity Corporation 2016 Omnibus Incentive Plan (the ?Plan?), and is s

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 February 23, 2022 Date of Report (date of earliest event reported) INGEVITY CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37586 47-4027764 (State or other jurisdiction of incorporation or organizati

CONSULTING AGREEMENT

Exhibit 10.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD BE LIKELY TO CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. SUCH EXCLUDED INFORMATION IS DENOTED BY ASTERISKS IN BRACKETS [*****]. CONSULTING AGREEMENT This CONSULTING AGREEMENT ("Agreement") is made effective as of March 1, 2022, between Ingevity Corpora

TABLE OF CONTENTS FINANCIAL SCHEDULES Page Condensed Consolidated Statements of Operations 1 Segment Operating Results 2 Condensed Consolidated Balance Sheets 3 Condensed Consolidated Statements of Cash Flows 4 Non-GAAP Financial Measures 5 Reconcili

Exhibit 99.1 Ingevity Corporation 4920 O'Hear Avenue Suite 400 North Charleston, SC 29405 USA www.ingevity.com News Contact: Caroline Monahan 843-740-2068 [email protected] Investors: Mary Dean Hall 843-INGEVITY [email protected] Ingevity reports fourth-quarter and full-year 2021 financial results HIGHLIGHTS: (comparisons versus prior year period) ?Company delivered solid results despite sup

NGVT / Ingevity Corp / Boston Partners - ROBECO INVESTMENT MANAGEMENT INC. Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Ingevity Corp (Name of Issuer) Common Stock (Title of Class of Securities) 45688C107 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule

NGVT / Ingevity Corp / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 7)* Name of issuer: Ingevity Corp. Title of Class of Securities: Common Stock CUSIP Number: 45688C107 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ??Rule

NGVT / Ingevity Corp / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* INGEVITY CORPORATION (Name of Issuer) Common Stock (Title of Class of Securities) 45688C107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this S

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 December 6, 2021 Date of Report (date of earliest event reported) INGEVITY CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37586 47-4027764 (State or other jurisdiction of incorporation or organizatio

Ingevity Corporation 4920 O'Hear Avenue Suite 400 North Charleston, SC 29405 USA www.ingevity.com News Contact: Caroline Monahan 843-740-2068 [email protected] Investors: Bill Hamilton 843-746-2138 [email protected]

Exhibit 99.1 Ingevity Corporation 4920 O'Hear Avenue Suite 400 North Charleston, SC 29405 USA www.ingevity.com News Contact: Caroline Monahan 843-740-2068 [email protected] Investors: Bill Hamilton 843-746-2138 [email protected] Mike Smith elects to retire as executive vice president and president, performance chemicals, strategy and business development of Ingevity NORTH CHARLESTON, S.C., D

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37586 INGEVITY CORPORATION (Exact name of registrant as

SECOND AMENDED AND RESTATED BYLAWS OF INGEVITY CORPORATION EFFECTIVE AS OF OCTOBER 25, 2021 ARTICLE I MEETINGS OF STOCKHOLDERS

Exhibit 3.2 SECOND AMENDED AND RESTATED BYLAWS OF INGEVITY CORPORATION EFFECTIVE AS OF OCTOBER 25, 2021 ARTICLE I MEETINGS OF STOCKHOLDERS Section 1.1Place of Meetings. The annual meeting of stockholders for the election of directors and all special meetings for that or for any other purpose shall be held at such time and place, either within or without the State of Delaware as may from time to ti

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 October 27, 2021 Date of Report (date of earliest event reported) INGEVITY CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37586 47-4027764 (State or other jurisdiction of incorporation or organizatio

TABLE OF CONTENTS FINANCIAL SCHEDULES Page Condensed Consolidated Statements of Operations 1 Segment Operating Results 2 Condensed Consolidated Balance Sheets 3 Condensed Consolidated Statements of Cash Flows 4 Non-GAAP Financial Measures 5 Reconcili

EX-99.1 2 ex99109302021.htm EX-99.1 Exhibit 99.1 Ingevity Corporation 4920 O'Hear Avenue Suite 400 North Charleston, SC 29405 USA www.ingevity.com News Contact: Caroline Monahan 843-740-2068 [email protected] Investors: Bill Hamilton 843-746-2138 [email protected] Ingevity reports third quarter 2021 financial results HIGHLIGHTS: (comparisons versus prior year period) •Third quarter net sales

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 September 15, 2021 Date of Report (date of earliest event reported) INGEVITY CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37586 47-4027764 (State or other jurisdiction of incorporation or organizat

Ingevity Corporation 4920 O'Hear Avenue Suite 400 North Charleston, SC 29405 USA www.ingevity.com News Contact: Caroline Monahan 843-740-2068 [email protected] Investors: Bill Hamilton 843-746-2138 [email protected]

EX-99.1 2 ex99109152021.htm EX-99.1 Exhibit 99.1 Ingevity Corporation 4920 O'Hear Avenue Suite 400 North Charleston, SC 29405 USA www.ingevity.com News Contact: Caroline Monahan 843-740-2068 [email protected] Investors: Bill Hamilton 843-746-2138 [email protected] Ingevity to challenge jury verdict on emissions control patent NORTH CHARLESTON, S.C., September 16, 2021 – Ingevity Corporation

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT T

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37586 INGEVITY CORPORATION (Exact name of registrant as speci

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 July 28, 2021 Date of Report (date of earliest event reported) INGEVITY CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37586 47-4027764 (State or other jurisdiction of incorporation or organization)

The results and guidance in this release include non-GAAP financial measures. Refer to the section entitled “Use of non-GAAP financial measures” within this release.

Exhibit 99.1 Ingevity Corporation 4920 O'Hear Avenue Suite 400 North Charleston, SC 29405 USA www.ingevity.com News Contact: Caroline Monahan 843-740-2068 [email protected] Investors: Bill Hamilton 843-746-2138 [email protected] Ingevity reports second quarter 2021 financial results and increases full year 2021 guidance HIGHLIGHTS: (comparisons versus prior year period) ?Ingevity delivers st

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6)*

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6)* Name of issuer: Ingevity Corp. Title of Class of Securities: Common Stock CUSIP Number: 45688C107 Date of Event Which Requires Filing of this Statement: April 30, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ??Rule 13

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37586 INGEVITY CORPORATION (Exact name of registrant as spec

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 April 28, 2021 Date of Report (date of earliest event reported) INGEVITY CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37586 47-4027764 (State or other jurisdiction of incorporation or organization)

The results and guidance in this release include Non-GAAP financial measures. Refer to the section entitled “Use of Non-GAAP Financial Measures” within this release.

Exhibit 99.1 Ingevity Corporation 4920 O'Hear Avenue Suite 400 North Charleston, SC 29406 USA www.ingevity.com News Contact: Amy Chiconas 843-746-8197 [email protected] Investors: Bill Hamilton 843-746-2138 [email protected] Ingevity reports first quarter 2021 financial results HIGHLIGHTS: (comparisons versus prior year) ?Ingevity delivers strong first quarter results based on demand improve

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 April 22, 2021 Date of Report (date of earliest event reported) INGEVITY CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37586 47-4027764 (State or other jurisdiction of incorporation or organization)

Ingevity Corporation 4920 O'Hear Avenue Suite 400 North Charleston, SC 29406 USA www.ingevity.com News Contact: Amy Chiconas 843-746-8197 [email protected] Investors: Jack Maurer 843-746-8242 [email protected]

Exhibit 99.1 Ingevity Corporation 4920 O'Hear Avenue Suite 400 North Charleston, SC 29406 USA www.ingevity.com News Contact: Amy Chiconas 843-746-8197 [email protected] Investors: Jack Maurer 843-746-8242 [email protected] Ingevity names Mary Dean Hall as executive vice president and chief financial officer NORTH CHARLESTON, S.C., March 24, 2021 – Ingevity Corporation (NYSE:NGVT) today annou

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 March 19, 2021 Date of Report (date of earliest event reported) INGEVITY CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37586 47-4027764 (State or other jurisdiction of incorporation or organization)

SEVERANCE AND CHANGE OF CONTROL AGREEMENT

Exhibit 10.1 [Certain information in this exhibit has been omitted pursuant to Item 601(b)(10) of Regulation S-K. Such information is not material and would likely cause competitive harm to the registrant if publicly disclosed.] SEVERANCE AND CHANGE OF CONTROL AGREEMENT THIS SEVERANCE AND CHANGE OF CONTROL AGREEMENT (the ?Agreement?) by and between Ingevity Corporation, a Delaware corporation (tog

- DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

- DEF 14A

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

Annual Report - 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37586 INGEVITY CORPORATION (Exact name of registrant as specified

DESCRIPTION OF THE REGISTRANT'S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934

Exhibit 4.3 DESCRIPTION OF THE REGISTRANT'S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Ingevity Corporation has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our Common Stock. The following description of our Common Stock is a summary and is qualified in its entirety by reference to our certificate o

SEVERANCE AND CHANGE OF CONTROL AGREEMENT

Exhibit 10.29 [Certain information in this exhibit has been omitted pursuant to Item 601(b)(10) of Regulation S-K. Such information is not material and would likely cause competitive harm to the registrant if publicly disclosed.] SEVERANCE AND CHANGE OF CONTROL AGREEMENT THIS SEVERANCE AND CHANGE OF CONTROL AGREEMENT (the "Agreement") by and between Ingevity Corporation, a Delaware corporation (to

AMENDMENT TO CRUDE TALL OIL SUPPLY AGREEMENT

Exhibit 10.31 EXECUTION VERSION [Certain information in this exhibit has been omitted pursuant to Item 601(b)(10) of Regulation S-K. Such information is not material and would likely cause competitive harm to the registrant if publicly disclosed.] AMENDMENT TO CRUDE TALL OIL SUPPLY AGREEMENT This Amendment (this ?Amendment?) to the Crude Tall Oil Supply Agreement, dated as of May 1, 2020 (the ?Eff

INGEVITY CORPORATION SUBSIDIARIES OF THE REGISTRANT Name of Subsidiary Jurisdiction of Organization Ingevity Corporation Delaware, United States of America Ingevity South Carolina, LLC Delaware, United States of America Ingevity Virginia Corporation

Exhibit 21.1 INGEVITY CORPORATION SUBSIDIARIES OF THE REGISTRANT Name of Subsidiary Jurisdiction of Organization Ingevity Corporation Delaware, United States of America Ingevity South Carolina, LLC Delaware, United States of America Ingevity Virginia Corporation Virginia, United States of America Ingevity Arkansas, LLC Delaware, United States of America Ingevity Services, Inc. Delaware, United Sta

Ingevity Corporation 4920 O'Hear Avenue Suite 400 North Charleston, SC 29406 USA www.ingevity.com News Contact: Amy Chiconas 843-746-8197 [email protected] Investors: Jack Maurer 843-746-8242 [email protected]

Exhibit 99.2 Ingevity Corporation 4920 O'Hear Avenue Suite 400 North Charleston, SC 29406 USA www.ingevity.com News Contact: Amy Chiconas 843-746-8197 [email protected] Investors: Jack Maurer 843-746-8242 [email protected] Jean Blackwell elected chair of Ingevity?s board of directors NORTH CHARLESTON, S.C., February 17, 2021 ? Ingevity Corporation (NYSE: NGVT) today announced that Jean Black

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 February 15, 2021 Date of Report (date of earliest event reported) INGEVITY CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37586 47-4027764 (State or other jurisdiction of incorporation or organizati

Ingevity Corporation 4920 O'Hear Avenue Suite 400 North Charleston, SC 29406 USA www.ingevity.com News Contact: Amy Chiconas 843-746-8197 [email protected] Investors: Jack Maurer 843-746-8242 [email protected]

Exhibit 99.1 Ingevity Corporation 4920 O'Hear Avenue Suite 400 North Charleston, SC 29406 USA www.ingevity.com News Contact: Amy Chiconas 843-746-8197 [email protected] Investors: Jack Maurer 843-746-8242 [email protected] Ingevity mourns passing of Chairman of the Board Rick Kelson NORTH CHARLESTON, S.C., February 15, 2021 – Ingevity Corporation (NYSE:NGVT) today announced that Richard B. K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 0)* Ingevity Corp (Name of Issuer) Common Stock (Title of Class of Securities) 45688C107 (CUSIP Number) Dece

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 0)* Ingevity Corp (Name of Issuer) Common Stock (Title of Class of Securities) 45688C107 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule

The results and guidance in this release include Non-GAAP financial measures. Refer to the section entitled “Use of Non-GAAP Financial Measures” within this release.

Exhibit 99.1 Ingevity Corporation 4920 O'Hear Avenue Suite 400 North Charleston, SC 29405 USA www.ingevity.com News Contact: Amy Chiconas 843-746-8197 [email protected] Investors: Jack Maurer 843-746-8242 [email protected] Ingevity reports preliminary fourth quarter and full year 2020 financial results •Ingevity delivers strong fourth quarter results driven by continued recovery of global au

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 February 10, 2021 Date of Report (date of earliest event reported) INGEVITY CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37586 47-4027764 (State or other jurisdiction of incorporation or organizati

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)*

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* Name of issuer: Ingevity Corp. Title of Class of Securities: Common Stock CUSIP Number: 45688C107 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule

SCHEDULE 13G

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* INGEVITY CORPORATION (Name of Issuer) Common Stock (Title of Class of Securities) 45688C107 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sch

Ingevity Corporation

EX-99.1 Exhibit 99.1 Ingevity Corporation 4920 O’Hear Avenue Suite 400 North Charleston, SC 29405 USA www.ingevity.com Contact: Laura Woodcock 843-746-8197 [email protected] Investors: Jack Maurer 843-746-8242 [email protected] Ingevity names Stacy Lancaster Cozad as executive vice president, general counsel and secretary NORTH CHARLESTON, S.C., January 13, 2021 – Ingevity Corpora

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 January 8, 2021 Date of Report (date of earliest event reported) INGEVITY CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37586 47-4027764 (State or other jurisdiction of incorporation or organization

SEVERANCE AND CHANGE OF CONTROL AGREEMENT

Exhibit 10.3 [Certain information in this exhibit has been omitted pursuant to Item 601(b)(10) of Regulation S-K. Such information is not material and would likely cause competitive harm to the registrant if publicly disclosed.] SEVERANCE AND CHANGE OF CONTROL AGREEMENT THIS SEVERANCE AND CHANGE OF CONTROL AGREEMENT (the “Agreement”) by and between Ingevity Corporation, a Delaware corporation (tog

SEVERANCE AND CHANGE OF CONTROL AGREEMENT

Exhibit 10.4 [Certain information in this exhibit has been omitted pursuant to Item 601(b)(10) of Regulation S-K. Such information is not material and would likely cause competitive harm to the registrant if publicly disclosed.] SEVERANCE AND CHANGE OF CONTROL AGREEMENT THIS SEVERANCE AND CHANGE OF CONTROL AGREEMENT (the “Agreement”) by and between Ingevity Corporation, a Delaware corporation (tog

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37586 INGEVITY CORPORATION (Exact name of registrant as

Amendment No. 5, dated as of October 28, 2020, among Ingevity Corporation, Ingevity Holdings SRL, the other loan parties party thereto, JPMorgan Chase Bank, N.A., as the administrative agent, Wells Fargo Bank, N.A., as the resigning administrative agent, and the lenders party thereto

EX-10.1 Exhibit 10.1 EXECUTION VERSION AMENDMENT NO. 5 AMENDMENT NO. 5, dated as of October 28, 2020 (this “Amendment”), among INGEVITY CORPORATION, a Delaware corporation (the “U.S. Borrower”), INGEVITY HOLDINGS SRL (formerly MEADWESTVACO EUROPE SPRL), a Belgian private limited liability company (société à responsabilité limitée/besloten vennootschap) incorporated under the laws of Belgium, with

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 28, 2020 Date of Report (date of earliest event reported) INGEVITY CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37586 47-4027764 (State or other jurisdiction of incorporation or organization

Indenture, dated as of October 28, 2020, among Ingevity Corporation, the guarantors party thereto and U.S. Bank National Association, as trustee, with respect to the 3.875% Senior Notes Due 2028 (incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K, as filed with the Commission on October 28, 2020).

EX-4.1 Exhibit 4.1 INGEVITY CORPORATION, as Issuer, the Guarantors named herein, and U.S. Bank National Association, as Trustee INDENTURE Dated as of October 28, 2020 3.875% Senior Notes due 2028 TABLE OF CONTENTS Page ARTICLE ONE DEFINITIONS AND INCORPORATION BY REFERENCE SECTION 1.01. Definitions 1 SECTION 1.02. Incorporation by Reference of Trust Indenture Act 34 SECTION 1.03. Rules of Construc

Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 October 20, 2020 Date of Report (date of earliest event reported) INGEVITY CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37586 47-4027764 (State or other jurisdiction of incorporation or organizatio

Ingevity Corporation

EX-99.1 Exhibit 99.1 Ingevity Corporation 4290 O’Hear Avenue Suite 400 North Charleston, S.C. 29405 USA www.ingevity.com News Contact: Laura Woodcock 843-746-8197 [email protected] Investors: Jack Maurer 843-746-8242 [email protected] Ingevity prices $550 million senior notes offering NORTH CHARLESTON, S.C., October 20, 2020—Ingevity Corporation (NYSE: NGVT) announced today the pric